Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adaptive ADT for Stage IV Castration Sensitive Prostate Cancer
NCT03511196Phase 1Active, not recruiting
- Sponsor
- Moffitt Cancer Center
- Start
- Sep 2018
- Primary completion
- Jun 2022
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in prostate cancer (PCa), sponsored by Moffitt Cancer Center. Primary endpoint: Rate of Participant Retention at 12 months. Started Sep 2018; status: active, not recruiting.
02
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03511196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03511196.